Latest news with #CincinnatiChildren's
Associated Press
02-06-2025
- Business
- Associated Press
FDA expands XENOVIEW® indication to include children from six years of age
DURHAM, NC and LONDON, June 02, 2025 (GLOBE NEWSWIRE) -- Polarean Imaging plc (AIM: POLX) ('Polarean' or the 'Company'), a commercial-stage medical imaging technology leader in functional Magnetic Resonance Imaging ('MRI') of the lungs, announces that the US Food and Drug Administration ('FDA') has approved the Company's Supplemental New Drug Application ('NDA') to expand the indication of XENOVIEW®. This approval immediately lowers the minimum patient age from 12 to six years old, significantly broadening access to this technology and expanding Polarean's total addressable market. The approval means that XENOVIEW can now be used with MRI for evaluation of lung ventilation in adults and pediatric patients aged six years and older, representing an increase in the number of eligible patients by approximately one million. The FDA supplement approval also includes the introduction of new XENOVIEW Dose Delivery Bag sizes tailored for smaller lungs of younger patients and corresponding updates to the HPX Polarization Measurement Station to measure various bag sizes. This approval reinforces Polarean's dedication to advancing functional lung imaging and increasing access to its technology, enabling enhanced care for a broader patient population. Christopher von Jako, Ph.D., Chief Executive Officer of Polarean, said: 'We are delighted that the FDA has approved our Supplemental NDA, allowing XENOVIEW to be used in younger pediatric patients, increasing the number of patients eligible to use our technology by approximately one million. This expanded indication further enhances our technology's clinical utility, offering clinicians an advanced tool to assess the lungs in children with chronic respiratory conditions, and strengthens its return on investment for hospitals. We look forward to launching a controlled US market release of the pediatric Dose Delivery Bags later this year, starting with Cincinnati Children's.' Erik Hysinger, MD, Pediatric Pulmonologist from Cincinnati Children's, said: 'This approval is an exciting step for children with chronic lung diseases, such as cystic fibrosis, asthma, bronchopulmonary dysplasia, and inflammation following bone-marrow transplant. For years, I've studied Xenon MRI in children ages 6 to 12, and expanding access to younger patients offers clinicians a powerful tool to characterize disease progression, monitor response to therapy, and guide interventions like airway dilation or tissue removal. This imaging platform enhances our ability to deliver more personalized, precise care for children with complex respiratory conditions.' For more information, visit About Polarean Polarean is a revenue-generating medical imaging technology company revolutionizing pulmonary medicine through direct visualization of lung function by introducing the power and safety of MRI to the respiratory healthcare community. This community is in desperate need of modern solutions to accurately assess lung function. The Company strives to optimize lung health and prevent avoidable loss by illuminating hidden disease, addressing the global unmet medical needs of more than 500 million patients worldwide suffering from chronic respiratory disease. Polarean is a leader in the field of hyperpolarization science and has successfully developed the first and only hyperpolarized Xenon MRI inhaled contrast agent, XENOVIEW®, which is now FDA-approved in the United States. Polarean is dedicated to researching, developing, and commercializing innovative imaging solutions with its non-invasive and radiation-free pulmonary functional MRI platform. This comprehensive drug-device platform encompasses the proprietary Xenon gas blend, gas hyperpolarization system, as well as software and accessories, facilitating fully integrated modern respiratory imaging operations. Founded in 2012, with offices in Durham, NC, and London, United Kingdom, Polarean is committed to increasing global awareness of and broad access to its XENOVIEW MRI technology platform. For the latest news and information about Polarean, please visit XENOVIEW IMPORTANT SAFETY INFORMATION Indication XENOVIEW™, prepared from the Xenon Xe 129 Gas Blend, is a hyperpolarized contrast agent indicated for use with magnetic resonance imaging (MRI) for evaluation of lung ventilation in adults and pediatric patients aged 6 years and older. Limitations of Use XENOVIEW has not been evaluated for use with lung perfusion imaging. CONTRAINDICATIONS None. Warnings and Precautions Risk of Decreased Image Quality from Supplemental Oxygen: Supplemental oxygen administered simultaneously with XENOVIEW inhalation can cause degradation of image quality. For patients on supplemental oxygen, withhold oxygen inhalation for two breaths prior to XENOVIEW inhalation, and resume oxygen inhalation immediately following the imaging breath hold. Risk of Transient Hypoxia: Inhalation of an anoxic gas such as XENOVIEW may cause transient hypoxemia in susceptible patients. Monitor all patients for oxygen desaturation and symptoms of hypoxemia and treat as clinically indicated. Adverse Reactions Adverse Reactions in Adult Patients: The adverse reactions (> one patient) in efficacy trials were oropharyngeal pain, headache, and dizziness. Adverse Reactions in Pediatric and Adolescent Patients: In published literature in pediatric patients aged 6 to 18, transient adverse reactions were reported: blood oxygen desaturation, heart rate elevation, numbness, tingling, dizziness, and euphoria. In at least one published study of pediatric patients aged 6 to 18 years, transient decrease in SpO2% and transient increase in heart rate was reported following hyperpolarized xenon Xe 129 administration. Please see full prescribing information at Contact Information: Polarean: Chuck Osborne Chief Financial Officer +1 (919) 206-7900, ext. 117 [email protected] [email protected] [email protected] General inquiries: [email protected] Follow Polarean on LinkedIn here Polarean: Chuck Osborne Chief Financial Officer +1 (919) 206-7900, ext. 117 [email protected] Polarean Investors: Anna Dunphy / Phillip Marriage +44 (0)20 7933 8780 [email protected] Polarean Media Contact: Alexis Opp +1 (919) 206-7900, ext. 145 [email protected] General inquiries: [email protected]
Yahoo
02-06-2025
- Business
- Yahoo
FDA expands XENOVIEW® indication to include children from six years of age
Increases number of eligible patients by approximately one million DURHAM, NC and LONDON, June 02, 2025 (GLOBE NEWSWIRE) -- Polarean Imaging plc (AIM: POLX) ('Polarean' or the 'Company'), a commercial-stage medical imaging technology leader in functional Magnetic Resonance Imaging ("MRI") of the lungs, announces that the US Food and Drug Administration ('FDA') has approved the Company's Supplemental New Drug Application ('NDA') to expand the indication of XENOVIEW®. This approval immediately lowers the minimum patient age from 12 to six years old, significantly broadening access to this technology and expanding Polarean's total addressable market. The approval means that XENOVIEW can now be used with MRI for evaluation of lung ventilation in adults and pediatric patients aged six years and older, representing an increase in the number of eligible patients by approximately one million. The FDA supplement approval also includes the introduction of new XENOVIEW Dose Delivery Bag sizes tailored for smaller lungs of younger patients and corresponding updates to the HPX Polarization Measurement Station to measure various bag sizes. This approval reinforces Polarean's dedication to advancing functional lung imaging and increasing access to its technology, enabling enhanced care for a broader patient population. Christopher von Jako, Ph.D., Chief Executive Officer of Polarean, said: "We are delighted that the FDA has approved our Supplemental NDA, allowing XENOVIEW to be used in younger pediatric patients, increasing the number of patients eligible to use our technology by approximately one million. This expanded indication further enhances our technology's clinical utility, offering clinicians an advanced tool to assess the lungs in children with chronic respiratory conditions, and strengthens its return on investment for hospitals. We look forward to launching a controlled US market release of the pediatric Dose Delivery Bags later this year, starting with Cincinnati Children's.' Erik Hysinger, MD, Pediatric Pulmonologist from Cincinnati Children's, said: 'This approval is an exciting step for children with chronic lung diseases, such as cystic fibrosis, asthma, bronchopulmonary dysplasia, and inflammation following bone-marrow transplant. For years, I've studied Xenon MRI in children ages 6 to 12, and expanding access to younger patients offers clinicians a powerful tool to characterize disease progression, monitor response to therapy, and guide interventions like airway dilation or tissue removal. This imaging platform enhances our ability to deliver more personalized, precise care for children with complex respiratory conditions.' For more information, visit PolareanPolarean is a revenue-generating medical imaging technology company revolutionizing pulmonary medicine through direct visualization of lung function by introducing the power and safety of MRI to the respiratory healthcare community. This community is in desperate need of modern solutions to accurately assess lung function. The Company strives to optimize lung health and prevent avoidable loss by illuminating hidden disease, addressing the global unmet medical needs of more than 500 million patients worldwide suffering from chronic respiratory disease. Polarean is a leader in the field of hyperpolarization science and has successfully developed the first and only hyperpolarized Xenon MRI inhaled contrast agent, XENOVIEW®, which is now FDA-approved in the United States. Polarean is dedicated to researching, developing, and commercializing innovative imaging solutions with its non-invasive and radiation-free pulmonary functional MRI platform. This comprehensive drug-device platform encompasses the proprietary Xenon gas blend, gas hyperpolarization system, as well as software and accessories, facilitating fully integrated modern respiratory imaging operations. Founded in 2012, with offices in Durham, NC, and London, United Kingdom, Polarean is committed to increasing global awareness of and broad access to its XENOVIEW MRI technology platform. For the latest news and information about Polarean, please visit IMPORTANT SAFETY INFORMATION IndicationXENOVIEW™, prepared from the Xenon Xe 129 Gas Blend, is a hyperpolarized contrast agent indicated for use with magnetic resonance imaging (MRI) for evaluation of lung ventilation in adults and pediatric patients aged 6 years and older. Limitations of UseXENOVIEW has not been evaluated for use with lung perfusion imaging. CONTRAINDICATIONSNone. Warnings and PrecautionsRisk of Decreased Image Quality from Supplemental Oxygen: Supplemental oxygen administered simultaneously with XENOVIEW inhalation can cause degradation of image quality. For patients on supplemental oxygen, withhold oxygen inhalation for two breaths prior to XENOVIEW inhalation, and resume oxygen inhalation immediately following the imaging breath hold. Risk of Transient Hypoxia: Inhalation of an anoxic gas such as XENOVIEW may cause transient hypoxemia in susceptible patients. Monitor all patients for oxygen desaturation and symptoms of hypoxemia and treat as clinically indicated. Adverse Reactions Adverse Reactions in Adult Patients: The adverse reactions (> one patient) in efficacy trials were oropharyngeal pain, headache, and dizziness. Adverse Reactions in Pediatric and Adolescent Patients: In published literature in pediatric patients aged 6 to 18, transient adverse reactions were reported: blood oxygen desaturation, heart rate elevation, numbness, tingling, dizziness, and euphoria. In at least one published study of pediatric patients aged 6 to 18 years, transient decrease in SpO2% and transient increase in heart rate was reported following hyperpolarized xenon Xe 129 administration. Please see full prescribing information at Contact Information:Polarean: Chuck Osborne Chief Financial Officer +1 (919) 206-7900, ext. 117 cosborne@ Polarean Investors: Anna Dunphy / Phillip Marriage +44 (0)20 7933 8780 polarean@ Media Contact: Alexis Opp +1 (919) 206-7900, ext. 145 aopp@ General inquiries: info@ Follow Polarean on LinkedIn here CONTACT: Polarean: Chuck Osborne Chief Financial Officer +1 (919) 206-7900, ext. 117 cosborne@ Polarean Investors: Anna Dunphy / Phillip Marriage +44 (0)20 7933 8780 polarean@ Polarean Media Contact: Alexis Opp +1 (919) 206-7900, ext. 145 aopp@ General inquiries: info@
Mid East Info
06-05-2025
- Health
- Mid East Info
PureHealth and SEHA Partner with Cincinnati Children's in US to Advance Abu Dhabi's Paediatric Care Ecosystem
New Global Collaboration Establishes Abu Dhabi as a Leading Hub for Advanced Paediatric Medicine Abu Dhabi – UAE, May 2025 – PureHealth, the largest healthcare group in the Middle East, and its subsidiary SEHA have partnered with the number one US children's hospital, Cincinnati Children's, through SEHA Sheikh Khalifa Medical City (SKMC), to deliver world-class paediatric expertise to Abu Dhabi and the UAE. The partnership between SEHA SKMC and Cincinnati Children's marks a major milestone in advancing clinical services, research, and medical training, and reflects their shared vision to reinforce Abu Dhabi's position as a global leader in advanced paediatric medicine and healthcare. Through this collaboration, both institutions will work closely in embedding international best practices across key paediatric specialities, including Cardiac Surgery, Neurosurgery, Oncology, and Transplant Medicine. By combining SEHA SKMC's established clinical foundation with the global expertise of Cincinnati Children's, the collaboration is not only raising the standard of care but also creating a shared culture of innovation, continuous learning, and improvement. During Abu Dhabi Global Health Week 2025 and in the presence of His Excellency Mansoor Al Mansoori, Chairman of the Department of Health – Abu Dhabi (DoH), Her Excellency Dr Noura Khamis Al Ghaithi, Undersecretary of the Department of Health – Abu Dhabi, Shaista Asif, Group Chief Executive Officer of PureHealth and Rashed Al Qubaisi, Group Chief Operating Officer at PureHealth, the agreement was signed by Saeed Al Kuwaiti, Chief Executive Officer of SEHA and Oliver Rhine, Chief Strategy Officer of Cincinnati Children's. His Excellency Mansoor Al Mansoori, Chairman of the Department of Health – Abu Dhabi (DoH), said: 'Under the directives of our wise leadership, Abu Dhabi is committed to providing specialised healthcare facilities that deliver world-class services, enabling community members to enjoy long, healthy lives. This is achieved by strengthening cooperative frameworks with major healthcare institutions worldwide. The collaboration between SEHA and Cincinnati Children's highlights the depth of our relationships with partners in the United States and our shared vision of improving health in communities everywhere.' Shaista Asif, Group Chief Executive Officer of PureHealth, said: 'PureHealth is proud to lead partnerships that raise standards and transform lives. This collaboration places Abu Dhabi at the forefront of paediatric healthcare in the region, reducing reliance on overseas treatment, strengthening local expertise, and building long-term resilience within our health system. By leveraging the expertise of both institutions, we aim to strengthen the region's position as a global leader in pediatric medicine, drive innovation, and deliver exceptional outcomes for children and families.' The partnership goes beyond individual clinical cases to reshape care models, develop integrated patient pathways, and pilot innovative protocols that aim to have a lasting, system-wide impact. Collectively, the two teams are advancing paediatric care through a globally aligned model focused on comprehensive, patient-centred outcomes, placing Abu Dhabi at the forefront of cutting-edge paediatrics in the Middle East. Steve Davis MD, President and CEO of Cincinnati Children's, said: 'At Cincinnati Children's, we have long had the goal of being the leader in improving child health, and over the past decades, we have made real progress in improving the health of children in Cincinnati, in the US and around the world. We have done that through partnerships with other organisations where we have taken an all-teach, all-learn approach. We are so excited about the opportunities with SEHA Sheikh Khalifa Medical City. We share their vision of helping to create a world-class Paediatric Centre of Excellence here in Abu Dhabi that will benefit the children of the United Arab Emirates, the region, and the children in Cincinnati.' The initiative is a cornerstone of PureHealth and SEHA's broader ambition to make Abu Dhabi a global reference point for healthcare excellence. The newly established Paediatric Centre of Excellence at SEHA SKMC is already contributing significantly to providing patients across the UAE and the Middle East with best-in-class, advanced, specialised care here in Abu Dhabi, reducing the need for overseas travel for treatment. About PureHealth: PureHealth is the largest healthcare group in the Middle East with an ecosystem that challenges lifespans and reimagines health spans. With 100+ hospitals, 300+ clinics, multiple diagnostic centres, health insurance solutions, pharmacies, health tech, procurement, investments and more, its groundbreaking innovations are at the forefront of healthcare as the company is on a mission to unlock time for humankind. By advancing the Science of Longevity, PureHealth is introducing the healthcare of the future from the United Arab Emirates to the rest of the world. PureHealth's network comprises: SEHA – One of the largest healthcare networks of hospitals and clinics in the UAE SEHA CLINICS – Delivering comprehensive community-based healthcare services Daman (The National Health Insurance Company) – The UAE's leading health insurer The Medical Office – Overseeing Sheikh Khalifa Hospitals and healthcare facilities established under the initiatives of H.H. The President of the UAE Rafed – The UAE's largest healthcare Group Purchasing Organisation PureLab – Managing and operating the largest network of laboratories in the region One Health – A network that provides end-to-end medical solutions to a base of over 300 healthcare service providers provides end-to-end medical solutions to a base of over 300 healthcare service providers The Life Corner – Abu Dhabi's first holistic pharmacy, serving the health and wellness establishment Ardent Health Services – The fourth largest privately held acute care hospital operator in the US Circle Health Group – The largest independent operators of hospitals in the UK Hellenic Healthcare Group (HHG) – the largest private healthcare provider in Greece and Cyprus PureCS – A leading cloud and technology services provider, specialising in IT management and consulting solutions, cybersecurity, cloud services and AI information systems Sheikh Shakhbout Medical City (SSMC) – The UAE's largest healthcare complex, delivering integrated complex care About SEHA: SEHA is an independent, public joint stock company created to develop the curative activities of the public healthcare system in Abu Dhabi. The company operates a big number of the public hospitals and clinics of the emirate of Abu Dhabi. SEHA is a PureHealth asset, the largest healthcare platform in the Middle East. SEHA is committed to the continuous improvement of customer care to recognised international standards, and providing the community with world-class healthcare. SEHA operates 14 hospitals with over 3,000 beds, 70 ambulatory care, family care and urgent care centres, and three blood banks. Its facilities accommodate 117,162 inpatients annually, conducting 43,262 surgeries, and treat more than 5 million outpatients. SEHA is one of the largest integrated healthcare providers in the Middle East, with more than 14,000 doctors, nurses, ancillary care, and administrative personnel. About Cincinnati Children's : Cincinnati Children's is ranked among the best pediatric health systems in the nation by U.S. News & World Report, including No. 1 in pediatric cancer care, gastroenterology and pulmonology. Cincinnati Children's also ranks among the nation's best for pediatric and adolescent behavioral health. Established in 1883, Cincinnati Children's is a nonprofit that cares for patients from all 50 states and dozens of countries, including kids with complex or rare disorders.
Zawya
06-05-2025
- Health
- Zawya
PureHealth and SEHA Partner with Cincinnati Children's in US to advance Abu Dhabi's paediatric care ecosystem
Abu Dhabi – UAE – PureHealth, the largest healthcare group in the Middle East, and its subsidiary SEHA have partnered with the number one US children's hospital, Cincinnati Children's, through SEHA Sheikh Khalifa Medical City (SKMC), to deliver world-class paediatric expertise to Abu Dhabi and the UAE. The partnership between SEHA SKMC and Cincinnati Children's marks a major milestone in advancing clinical services, research, and medical training, and reflects their shared vision to reinforce Abu Dhabi's position as a global leader in advanced paediatric medicine and healthcare. Through this collaboration, both institutions will work closely in embedding international best practices across key paediatric specialities, including Cardiac Surgery, Neurosurgery, Oncology, and Transplant Medicine. By combining SEHA SKMC's established clinical foundation with the global expertise of Cincinnati Children's, the collaboration is not only raising the standard of care but also creating a shared culture of innovation, continuous learning, and improvement. During Abu Dhabi Global Health Week 2025 and in the presence of His Excellency Mansoor Al Mansoori, Chairman of the Department of Health – Abu Dhabi (DoH), Her Excellency Dr Noura Khamis Al Ghaithi, Undersecretary of the Department of Health – Abu Dhabi, Shaista Asif, Group Chief Executive Officer of PureHealth and Rashed Al Qubaisi, Group Chief Operating Officer at PureHealth, the agreement was signed by Saeed Al Kuwaiti, Chief Executive Officer of SEHA and Oliver Rhine, Chief Strategy Officer of Cincinnati Children's. His Excellency Mansoor Al Mansoori, Chairman of the Department of Health – Abu Dhabi (DoH), said: 'Under the directives of our wise leadership, Abu Dhabi is committed to providing specialised healthcare facilities that deliver world-class services, enabling community members to enjoy long, healthy lives. This is achieved by strengthening cooperative frameworks with major healthcare institutions worldwide. The collaboration between SEHA and Cincinnati Children's highlights the depth of our relationships with partners in the United States and our shared vision of improving health in communities everywhere.' Shaista Asif, Group Chief Executive Officer of PureHealth, said: 'PureHealth is proud to lead partnerships that raise standards and transform lives. This collaboration places Abu Dhabi at the forefront of paediatric healthcare in the region, reducing reliance on overseas treatment, strengthening local expertise, and building long-term resilience within our health system. By leveraging the expertise of both institutions, we aim to strengthen the region's position as a global leader in pediatric medicine, drive innovation, and deliver exceptional outcomes for children and families." The partnership goes beyond individual clinical cases to reshape care models, develop integrated patient pathways, and pilot innovative protocols that aim to have a lasting, system-wide impact. Collectively, the two teams are advancing paediatric care through a globally aligned model focused on comprehensive, patient-centred outcomes, placing Abu Dhabi at the forefront of cutting-edge paediatrics in the Middle East. Steve Davis MD, President and CEO of Cincinnati Children's, said: 'At Cincinnati Children's, we have long had the goal of being the leader in improving child health, and over the past decades, we have made real progress in improving the health of children in Cincinnati, in the US and around the world. We have done that through partnerships with other organisations where we have taken an all-teach, all-learn approach. We are so excited about the opportunities with SEHA Sheikh Khalifa Medical City. We share their vision of helping to create a world-class Paediatric Centre of Excellence here in Abu Dhabi that will benefit the children of the United Arab Emirates, the region, and the children in Cincinnati.' The initiative is a cornerstone of PureHealth and SEHA's broader ambition to make Abu Dhabi a global reference point for healthcare excellence. The newly established Paediatric Centre of Excellence at SEHA SKMC is already contributing significantly to providing patients across the UAE and the Middle East with best-in-class, advanced, specialised care here in Abu Dhabi, reducing the need for overseas travel for treatment. About PureHealth: PureHealth is the largest healthcare group in the Middle East with an ecosystem that challenges lifespans and reimagines health spans. With 100+ hospitals, 300+ clinics, multiple diagnostic centres, health insurance solutions, pharmacies, health tech, procurement, investments and more, its groundbreaking innovations are at the forefront of healthcare as the company is on a mission to unlock time for humankind. By advancing the Science of Longevity, PureHealth is introducing the healthcare of the future from the United Arab Emirates to the rest of the world. PureHealth's network comprises: SEHA – One of the largest healthcare networks of hospitals and clinics in the UAE SEHA CLINICS - Delivering comprehensive community-based healthcare services Daman (The National Health Insurance Company) – The UAE's leading health insurer The Medical Office – Overseeing Sheikh Khalifa Hospitals and healthcare facilities established under the initiatives of H.H. The President of the UAE Rafed – The UAE's largest healthcare Group Purchasing Organisation PureLab – Managing and operating the largest network of laboratories in the region One Health – A network that provides end-to-end medical solutions to a base of over 300 healthcare service providers The Life Corner – Abu Dhabi's first holistic pharmacy, serving the health and wellness establishment Ardent Health Services – The fourth largest privately held acute care hospital operator in the US Circle Health Group – The largest independent operators of hospitals in the UK Hellenic Healthcare Group (HHG) - the largest private healthcare provider in Greece and Cyprus PureCS - A leading cloud and technology services provider, specialising in IT management and consulting solutions, cybersecurity, cloud services and AI information systems Sheikh Shakhbout Medical City (SSMC) – The UAE's largest healthcare complex, delivering integrated complex care About SEHA SEHA is an independent, public joint stock company created to develop the curative activities of the public healthcare system in Abu Dhabi. The company operates a big number of the public hospitals and clinics of the emirate of Abu Dhabi. SEHA is a PureHealth asset, the largest healthcare platform in the Middle East. SEHA is committed to the continuous improvement of customer care to recognised international standards, and providing the community with world-class healthcare. SEHA operates 14 hospitals with over 3,000 beds, 70 ambulatory care, family care and urgent care centres, and three blood banks. Its facilities accommodate 117,162 inpatients annually, conducting 43,262 surgeries, and treat more than 5 million outpatients. SEHA is one of the largest integrated healthcare providers in the Middle East, with more than 14,000 doctors, nurses, ancillary care, and administrative personnel. About Cincinnati Children's Cincinnati Children's is ranked among the best pediatric health systems in the nation by U.S. News & World Report, including No. 1 in pediatric cancer care, gastroenterology and pulmonology. Cincinnati Children's also ranks among the nation's best for pediatric and adolescent behavioral health. Established in 1883, Cincinnati Children's is a nonprofit that cares for patients from all 50 states and dozens of countries, including kids with complex or rare disorders.
Al Etihad
06-05-2025
- Health
- Al Etihad
PureHealth, SEHA partner with Cincinnati Children's in US to advance Abu Dhabi's paediatric care ecosystem
6 May 2025 10:04 ABU DHABI (ALETIHAD)PureHealth and its subsidiary SEHA have partnered with the US children's hospital, Cincinnati Children's, through SEHA Sheikh Khalifa Medical City (SKMC), to deliver world-class paediatric expertise to Abu Dhabi and the partnership between SEHA SKMC and Cincinnati Children's marks a major milestone in advancing clinical services, research, and medical training, and reflects their shared vision to reinforce Abu Dhabi's position as a global leader in advanced paediatric medicine and healthcare. During Abu Dhabi Global Health Week 2025 and in the presence of His Excellency Mansoor Al Mansoori, Chairman of the Department of Health – Abu Dhabi (DoH), Her Excellency Dr Noura Khamis Al Ghaithi, Undersecretary of the Department of Health – Abu Dhabi, Shaista Asif, Group Chief Executive Officer of PureHealth and Rashed Al Qubaisi, Group Chief Operating Officer at PureHealth, the agreement was signed by Saeed Al Kuwaiti, Chief Executive Officer of SEHA and Oliver Rhine, Chief Strategy Officer of Cincinnati Children' this collaboration, both institutions will work closely in embedding international best practices across key paediatric specialities, including Cardiac Surgery, Neurosurgery, Oncology, and Transplant combining SEHA SKMC's established clinical foundation with the global expertise of Cincinnati Children's, the collaboration is not only raising the standard of care but also creating a shared culture of innovation, continuous learning, and Excellency Mansoor Al Mansoori, Chairman of the Department of Health – Abu Dhabi (DoH), said: 'Under the directives of our wise leadership, Abu Dhabi is committed to providing specialised healthcare facilities that deliver world-class services, enabling community members to enjoy long, healthy lives. "This is achieved by strengthening cooperative frameworks with major healthcare institutions worldwide. The collaboration between SEHA and Cincinnati Children's highlights the depth of our relationships with partners in the United States and our shared vision of improving health in communities everywhere.'Shaista Asif, Group Chief Executive Officer of PureHealth, said: 'PureHealth is proud to lead partnerships that raise standards and transform lives. This collaboration places Abu Dhabi at the forefront of paediatric healthcare in the region, reducing reliance on overseas treatment, strengthening local expertise, and building long-term resilience within our health system. By leveraging the expertise of both institutions, we aim to strengthen the region's position as a global leader in pediatric medicine, drive innovation, and deliver exceptional outcomes for children and families."The partnership goes beyond individual clinical cases to reshape care models, develop integrated patient pathways, and pilot innovative protocols that aim to have a lasting, system-wide impact. Collectively, the two teams are advancing paediatric care through a globally aligned model focused on comprehensive, patient-centred outcomes, placing Abu Dhabi at the forefront of cutting-edge paediatrics in the Middle East. Steve Davis MD, President and CEO of Cincinnati Children's, said: 'At Cincinnati Children's, we have long had the goal of being the leader in improving child health, and over the past decades, we have made real progress in improving the health of children in Cincinnati, in the US and around the world. We have done that through partnerships with other organisations where we have taken an all-teach, all-learn approach. "We are so excited about the opportunities with SEHA Sheikh Khalifa Medical City. We share their vision of helping to create a world-class Paediatric Centre of Excellence here in Abu Dhabi that will benefit the children of the United Arab Emirates, the region, and the children in Cincinnati.'The initiative is a cornerstone of PureHealth and SEHA's broader ambition to make Abu Dhabi a global reference point for healthcare excellence. The newly established Paediatric Centre of Excellence at SEHA SKMC is already contributing significantly to providing patients across the UAE and the Middle East with best-in-class, advanced, specialised care here in Abu Dhabi, reducing the need for overseas travel for treatment.
